Equities research analysts expect Histogenics Corp (NASDAQ:HSGX) to announce earnings per share (EPS) of ($0.21) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Histogenics’ earnings. Histogenics reported earnings of ($0.26) per share during the same quarter last year, which indicates a positive year over year growth rate of 19.2%. The business is scheduled to issue its next earnings report on Thursday, May 10th.

According to Zacks, analysts expect that Histogenics will report full-year earnings of ($0.82) per share for the current fiscal year, with EPS estimates ranging from ($1.02) to ($0.62). For the next year, analysts expect that the company will post earnings of ($0.77) per share, with EPS estimates ranging from ($1.01) to ($0.52). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Histogenics.

How to Become a New Pot Stock Millionaire

Histogenics (NASDAQ:HSGX) last posted its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.05.

Several equities research analysts have recently weighed in on HSGX shares. HC Wainwright set a $4.00 price objective on Histogenics and gave the company a “buy” rating in a report on Wednesday, December 27th. Zacks Investment Research cut Histogenics from a “buy” rating to a “hold” rating in a research note on Thursday, December 28th. ValuEngine upgraded Histogenics from a “strong sell” rating to a “sell” rating in a research note on Wednesday. Finally, Canaccord Genuity restated a “buy” rating and set a $4.00 price target on shares of Histogenics in a research note on Thursday, December 21st.

Institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC raised its stake in shares of Histogenics by 413.4% during the fourth quarter. Virtu Financial LLC now owns 63,563 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 51,182 shares during the last quarter. Deutsche Bank AG raised its stake in shares of Histogenics by 71.1% during the fourth quarter. Deutsche Bank AG now owns 71,706 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 29,806 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Histogenics by 54.8% during the fourth quarter. Renaissance Technologies LLC now owns 242,500 shares of the biotechnology company’s stock worth $497,000 after purchasing an additional 85,800 shares during the last quarter. Finally, Sabby Management LLC raised its stake in shares of Histogenics by 98.3% during the fourth quarter. Sabby Management LLC now owns 955,060 shares of the biotechnology company’s stock worth $1,958,000 after purchasing an additional 473,393 shares during the last quarter. Institutional investors and hedge funds own 50.45% of the company’s stock.

Histogenics (NASDAQ:HSGX) traded up $0.04 during mid-day trading on Friday, hitting $2.94. The stock had a trading volume of 79,598 shares, compared to its average volume of 148,768. The firm has a market capitalization of $74.70, a P/E ratio of -2.13 and a beta of 1.83. Histogenics has a 1-year low of $1.55 and a 1-year high of $3.35.

TRADEMARK VIOLATION NOTICE: This article was originally published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/histogenics-corp-hsgx-expected-to-post-earnings-of-0-21-per-share/1937411.html.

About Histogenics

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Get a free copy of the Zacks research report on Histogenics (HSGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.